ARCHIVES

AVEO’s Tivozanib Sunk by Fundamental Flaw: Higher Overall Survival in the Control Arm

This article is from The Cancer Letter archive.

Vol. 39 No. 18 | May 8, 2013

Download PDF Visit The Full Archive

Related Articles

Surveillance Treatment Option For Low-Risk Prostate Cancer

July 30, 2010

Kentucky Okays Cancer Commission, $1 Million Budget

April 21, 1978

Gene Therapy Hyped By Scientists, Panel Tells NIH; Emphasis Must Be Basic Research

December 15, 1995

NCAB Congress to Keep Cigarette Tax At 16 Cents

May 24, 1985

Tobacco Council Awards 34 New Grants

April 16, 1982

New Saccharin Studies Convince FDA It A Carcinogen

July 15, 1977